Keratinocyte Models for NLRP1 Inflammasome Studies

Inflammasome experiments in skin biology are highly dependent on the cellular model. In the 2024 study Comparison of Different Keratinocyte Cell Line Models for Analysis of NLRP1 Inflammasome Activation, Tian Wang, Amir S. Yazdi, and Diana Panayotova-Dimitrova tested whether commonly used immortalized keratinocyte lines reproduce the NLRP1 response observed in primary human keratinocytes. The study is especially useful because it evaluates model suitability directly rather than assuming that a convenient, genetically stable cell line will preserve the relevant innate immune pathway.

Study Background and Research Question

Keratinocytes form the dominant cellular compartment of the epidermis, but they are also active participants in cutaneous immunity. In response to physical injury, pathogens, or other stress signals, they can produce cytokines and chemokines and assemble inflammasome complexes. NLRP1 is considered the most prominent inflammasome sensor in human keratinocytes, making it an important system for studying sterile inflammation and skin disease.

Once an inflammasome is activated, caspase-1 can process interleukin-1β, interleukin-18, and gasdermin D. The resulting gasdermin D pores facilitate cytokine release and may lead to pyroptotic cell death. NLRP1 activation has been associated with ultraviolet B irradiation, viral proteases, double-stranded RNA, and inhibitors of dipeptidyl peptidases DPP8 and DPP9. Abnormal NLRP1 signaling is also linked to several rare inflammatory and keratinization disorders, which increases the need for physiologically appropriate in vitro models.

Primary keratinocytes are the closest of the tested systems to normal human skin, but they have practical disadvantages: limited lifespan, donor-to-donor variability, and greater difficulty in culture and genome engineering. HaCaT, HaSKpw, and SVTERT cells are easier to maintain and manipulate. The central research question was therefore whether these immortalized lines can provide a reliable substitute for primary keratinocytes when measuring NLRP1 inflammasome activation.

Key Innovation from the Reference Study

The main innovation is the direct, side-by-side comparison of four keratinocyte models using both biological and pharmacological stimuli. The authors did not evaluate only basal NLRP1 abundance or only cell viability. Instead, they examined inflammasome-related protein expression, stimulus-associated cell death, and molecular evidence of NLRP1 activation. This integrated design addresses a common interpretive problem: loss of viability is not equivalent to productive inflammasome signaling.

The inclusion of ultraviolet B and talabostat is also informative. In this study, talabostat was used as an experimental inflammasome inducer, referred to as PT-100 in related research contexts. Its use should be interpreted operationally within this keratinocyte assay; the paper does not establish that every downstream response is caused by DPP4 or FAP inhibition. This distinction is important when connecting the study to broader work on dipeptidyl peptidase biology.

Most importantly, the work tests the assumption that immortalized keratinocytes preserve the innate immune phenotype needed for NLRP1 research. The conclusion is not simply that primary cells produce stronger signals. Rather, the authors show that model choice can determine whether NLRP1 activation is detectable at all.

Methods and Experimental Design Insights

The investigators compared human primary keratinocytes obtained from healthy donors with the immortalized HaCaT, HaSKpw, and SVTERT lines. Cells were exposed to ultraviolet B irradiation or talabostat, and the effects on cell death, NLRP1-related molecules, and inflammatory readouts were assessed. The experimental strategy combined fluorescence-activated cell sorting, Western blotting, and enzyme-linked immunosorbent assay, allowing cellular and biochemical measurements to be interpreted together.

Flow cytometry was used to assess cell-death-related changes at the population level. Western blotting provided information about the abundance or processing of inflammasome-associated proteins, while ELISA enabled measurement of secreted inflammatory mediators. This combination is stronger than relying on a single endpoint because it can distinguish reduced cell viability from cytokine processing and release.

Protocol Parameters

• Cell-model comparison: Include primary human keratinocytes alongside the immortalized HaCaT, HaSKpw, and SVTERT models when the objective is to compare NLRP1 competence; the model set follows the reference study.
• Experimental stimuli: Use ultraviolet B and talabostat as separate treatment conditions rather than treating them as mechanistically interchangeable. Exact exposure settings should be taken from the full Materials and Methods section of the reference article.
• Readout integration: Pair flow-cytometric cell-death analysis with Western blotting and ELISA. A viability change alone should not be reported as definitive evidence of inflammasome activation.
• Baseline characterization: Measure basal expression of key NLRP1 inflammasome components before stimulation, because differences in pathway abundance may explain apparent differences in inducibility.
• Interpretation of negative results: If an immortalized line fails to show activation, confirm assay performance in primary keratinocytes before concluding that the stimulus is inactive.

For reproducibility, researchers should also document donor status for primary cells, passage history, confluence, ultraviolet B calibration, treatment timing, and normalization procedures. These workflow recommendations extend the study’s model-selection logic and should not be confused with additional parameters reported in the article.

Core Findings and Why They Matter

The reference study found that expression of key inflammasome components varied substantially among the models, with the highest levels detected in primary keratinocytes. This observation provides a molecular explanation for why primary cells were more responsive: the relevant pathway may be more completely represented before stimulation.

Both ultraviolet B and talabostat induced cell death across the experimental work, but readily detectable NLRP1 inflammasome activation was observed in primary keratinocytes and not in the analyzed immortalized lines. The result is methodologically important because it demonstrates that stimulus sensitivity and inflammasome competence are separate properties. An immortalized line can undergo stress-associated death while remaining unsuitable for measuring the specific NLRP1 pathway.

The authors therefore do not recommend HaCaT, HaSKpw, or SVTERT cells for analyzing keratinocyte inflammasome activation under the tested conditions. They strongly recommend primary keratinocytes instead. For researchers, the practical implication is that a negative result in an immortalized line should be treated cautiously. It may reflect pathway remodeling caused by immortalization, altered differentiation state, or insufficient expression of inflammasome components rather than a genuine absence of NLRP1 biology in human skin.

The findings also sharpen experimental reporting standards. Studies should identify whether they measured cell death, NLRP1 abundance, caspase-1-associated processing, or cytokine release. These endpoints are related but not interchangeable. A model that is adequate for general keratinocyte toxicity testing may not be adequate for mechanistic inflammasome research.

Comparison with Existing Internal Articles

The internal article FAPα-Sensitive Nanoparticle Probes Enable Noninvasive Tumor Diagnosis discusses FAPα-sensitive probes for detecting FAP-positive solid tumors. Its emphasis is biomarker-responsive tumor diagnostics, whereas Wang and colleagues focus on the integrity of the NLRP1 pathway in keratinocyte cell models. The articles are complementary only at the level of experimental model selection and protease-related biology; the tumor-probe work does not validate an immortalized keratinocyte model for inflammasome assays.

A second contextual resource, Talabostat Mesylate: Precision DPP4 & FAP Inhibition in Cancer and Immunology, places PT-100 in the wider literature on DPP4 and FAP biology. That context may help researchers understand why talabostat appears in cancer and immune-regulation discussions, but the keratinocyte paper answers a narrower question: which cell system can reveal NLRP1 inflammasome activation after ultraviolet B or talabostat exposure? The study should therefore be read as a model-validation paper, not as evidence for tumor efficacy.

Limitations and Transferability

The study has several boundaries. Primary keratinocytes were derived from healthy human donors, so the findings may not represent keratinocytes from inflamed, genetically predisposed, chronically sun-exposed, or tumor-adjacent skin. Donor biology, differentiation state, and culture conditions can influence inflammasome abundance and response strength.

The comparison also covers only three immortalized lines and two inducers. It does not establish that every immortalized keratinocyte model is incapable of NLRP1 activation, nor does it test every relevant trigger. In addition, the absence of readily detected activation may reflect assay sensitivity, altered protein processing, or differences in stimulus uptake and stress responses. The conclusions are strongest for the tested conditions and readouts.

Why this cross-domain matters, maturity, and limitations

Researchers searching for DPP4 inhibition in cancer research, FAP-expressing tumor growth inhibition, or tumor microenvironment modulation should not transfer the keratinocyte result directly to tumor models. The reference study does not measure tumor growth, stromal FAP activity, immune-cell recruitment, or hematopoiesis induction via G-CSF. Its evidence supports careful selection of keratinocyte models for NLRP1 experiments, while the cancer-related applications remain a separate research domain requiring its own cell systems and controls.

The most defensible translational implication is methodological: when a compound is used across cancer, immunology, and skin-inflammation studies, its biological effect should be interpreted in the context of the target cell, pathway expression, and assay endpoint. Primary keratinocytes offer higher physiological relevance for NLRP1 activation, whereas immortalized cells may remain useful for routine culture or genetic manipulation when the specific inflammasome endpoint is not the central question.

Research Support Resources

For researchers reproducing the pharmacological-stimulation arm, Talabostat mesylate (PT-100; SKU B3941) can support similar in vitro workflows. Consult the linked product information for formulation, storage, and research-use handling details, and use the full reference protocol to define treatment and detection conditions.